Streetbeat News

Price Targets

MGNX

MacroGenics' stock (MGNX) has seen an increase in its trading price following an upgrade from Citigroup, which changed its rating from Neutral to Buy and increased the price target from $7 to $13.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:51 pm

QIPT

Benchmark analyst Bill Sutherland has reiterated a Buy rating on Quipt Home Medical (NASDAQ:QIPT) and maintained a $10 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:48 pm

ACN

UBS analyst Kevin Mcveigh has maintained a Neutral rating on Accenture (NYSE:ACN) and increased the price target from $333 to $365.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:46 pm

RVMD

UBS analyst Eliana Merle has initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:45 pm

POOL

Stifel analyst W. Andrew Carter has maintained a Hold rating on Pool Corporation (NASDAQ:POOL) and increased the price target from $315 to $370.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:41 pm

IFF

Stifel analyst Mark Astrachan has maintained a Hold rating on Intl Flavors & Fragrances (IFF) and increased the price target from $81 to $87. This adjustment reflects a positive outlook on the company's future performance while still recommending a neutral position on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:40 pm

HD

Stifel analyst John Baugh has maintained a Hold rating on Home Depot (NYSE:HD) and increased the price target from $306 to $355.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:38 pm

AXSM

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $108.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:32 pm

ASND

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $152.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 3:27 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo provides daily proprietary analysis and trade strategy for SPY, QQQ, AAPL, MSFT, TSLA, NVDA, GOOGL, and META, based on price, volume, and options flow. The analysis includes specific price levels for potential breakouts or reversals. The memo also notes that there's limited new data today, with the weekly MBA mortgage applications report, the Conference Board's consumer confidence assessment, and comments from Fed's Goolsbee, along with a Treasury 20-year bond auction that could affect the market.

Portfolio Pulse from RIPS

December 20, 2023 | 3:22 pm